Rob Curran
Writer at Freelance
Reporter at Dow Jones Newswires
Journalist. Co-author of Journey without End: Migration from the Global South through the Americas.
Articles
-
1 day ago |
in.marketscreener.com | Rob Curran
By Rob Curran Pegasystems shares surged before the bell after the maker of artificial-intelligence software posted a robust climb in first-quarter revenue, pushing its bottom line into the green. Shares of Pegasystems were up 30% to $89.68 premarket. Late Tuesday, the Waltham, Mass., software maker swung to a profit of $85.4 million, or 91 cents a share, from a loss of $12.1 million, or 14 cents a share, a year earlier. Revenue leapt 44% to $475.6 million.
-
1 day ago |
tradingview.com | Rob Curran
Thermo Fisher 1Q Net, Revenue Up, Costs StableTMOThermo Fisher Scientific posted 14% net-income growth in the first quarter as revenue inched up and costs remained stable. The Waltham, Mass., maker of microscopes and other life-sciences and laboratory equipment said earnings rose to $1.51 billion, or $3.98 a share, from $1.33 billion, or $3.46 a share, a year earlier.
-
1 day ago |
tradingview.com | Denny Jacob |Rob Curran
Northrop Grumman Trims 2025 Outlook Following Slower Sales, Higher Bomber-Program CostsUpdateNOCBy Denny Jacob and Rob CurranNorthrop Grumman first-quarter earnings and sales missed analysts' estimates as delayed awards and higher-than-expected costs weighed on results, prompting it to cut its outlook for the year.
-
2 days ago |
marketscreener.com | Rob Curran
By Rob Curran OS Therapies shares jumped after the company said the Food and Drug Administration has agreed to a meeting to discuss the status of a bone cancer treatment candidate. Shares of OS Therapies rose 19% to $1.78 in premarket trading Tuesday.
-
2 days ago |
marketscreener.com | Rob Curran
By Rob Curran Orchestra BioMed Holdings shares rallied premarket after the maker of medical devices said a blood-pressure mechanism received breakthrough status from the U.S. Food and Drug Administration, allowing for a speedier review. The New Hope, Pa., company said Tuesday it received the FDA's Breakthrough Device Designation for an atrioventricular interval modulation therapy.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 239
- Tweets
- 394
- DMs Open
- Yes
RT @grainnemcc: It’s been 29 weeks. Evan was arrested in the spring, spent the summer in captivity and is now facing the winter. All in a M…
RT @RBmediaAuthors: You don't have to wait until release day to buy "Journey without End: Migration from the Global South through the Ameri…
So honored by Journey without End's launch at Vanderbilt University Press Tuesday. Now available on https://t.co/0zuZkDOEPx! Read about an incredible journey through Andean passes, Panamanian jungles, Mexican deserts and American detention centres.